TG Therapeutics Reports Stable or Improved Disability in 89% of Evaluable Patients in Phase 1 Azer-cel MS Trial at Day 90

• TG Therapeutics announced preliminary Phase 1 results for azer-cel in progressive multiple sclerosis, already presented at MSToronto2026, held October 21-23.
• Most evaluable patients had stable or improved disability despite prior progression on high-efficacy therapies, including anti-CD20 treatments.
• The 26-participant study showed no dose-limiting toxicities or high-grade CAR T-cell-related toxicities.
• Findings remain limited by the small study population and short follow-up; dose escalation and longer-term follow-up are ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023597209) on October 23, 2026, and is solely responsible for the information contained therein.